Journal article
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies
Abstract
PurposeTo establish the safety, maximum tolerated dose (MTD), recommended phase II dose, and preliminary antitumor activity of obatoclax mesylate (GX15-070MS), a Bcl-2 antagonist, in combination with topotecan in patients with solid tumor malignancies.Patients and methodsPatients with solid tumor malignancies for whom topotecan was an appropriate treatment were administered obatoclax mesylate and topotecan on a 3-week cycle in a pre-defined, …
Authors
Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S
Journal
Cancer Chemotherapy and Pharmacology, Vol. 66, No. 6, pp. 1079–1085
Publisher
Springer Nature
Publication Date
11 2010
DOI
10.1007/s00280-010-1265-5
ISSN
0344-5704